1.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: AAAC1114, NCT00583349
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-165, NCT01259063
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA-ALT-801-01-12, NCT01625260
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BC-07-01.CTIL, NCT00595088
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: Sutent V5 / November 9, 2009, NCT00794950
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16295, RV-BLD-PI-0330, NCT01373294
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2012.038, HUM00062285, NCT01663285
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: rAd-IFN-CS-002, NCT01687244
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TMX-101-003, NCT01731652
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU12-157, NCT01732107
|
|
11.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 129408, NCI-2010-00759, NCT01108003
|
|
12.
|
Phase: No phase specified Type: Treatment Status: Active Age: 40 and over Sponsor: Other Protocol IDs: 14585, NCT01240824
|